Vertex Pharmaceuticals is launching a new Phase 3 trial to assess the triple combination of VX-659 plus tezacaftor (VX-661)…
Articles by Alice Melão, MSc
Vertex Pharmaceuticals is offering the England arm of Britain’s National Health Service a package deal on the pricing of its…
Santhera Pharmaceuticals has bought the rights to POL6014, a medication being developed by Polyphor to treat cystic fibrosis…
The sweat test, a clinical standard for diagnosing cystic fibrosis (CF), was found to be equally reliable for diagnosing CF…
An independent review board has given a green light to Anthera Pharmaceuticals continuing a Phase 3 clinical trial evaluating Sollpura’s…
Changes in bacteria present in the lower respiratory tract during the first years of life may be indicative of early…
ProQR Therapeutics and Galapagos are working together on a new approach to treating the tissue scarring seen in cystic…
Some 3,400 European children whose cystic fibrosis (CF) is caused by the CFTR F508del mutation may now receive Orkambi (…
A number of cystic fibrosis discoveries, therapy advances and other developments were reported by Cystic Fibrosis News Today during 2017. Now that…
Preventing bacteria from communicating with each other may be a way to bolster the effectiveness of current cystic fibrosis (CF)…